Covid-19 News

  • This is all the fault of the anti-vaccination Death Cult.

    Obviously not: The vaccine terrorist deny early treatment what would save > 99% of all lives, The only guilty ones are the fascist US free masons (+R/X/B) that high jacked all pharma( FDA,CDC, NIH, most hospitals ) that just want to grab your money.


    USA the once free state that now kills people by depriving them live saving drugs!!


    It's a big shame to be a US citizen today. A state that denies science and human rights. China only kills then Uigurs. USA targets all its citizens!



    Are you sure that all 63 infected at this party were "double vaxxers"?

    Why must I be sure?? In the MA event it hit (>300) only double vaxxers. But please ask the DE government. I would like to know it too.


    The Lives Lost to Undervaccination, in Charts

    = Lives lost by not early treating CoV-19!!

  • Saudi Retrospective Study Compares Favipiravir & Hydroxychloroquine


    Saudi Retrospective Study Compares Favipiravir & Hydroxychloroquine
    Recently, a group of Saudi Arabian researchers from King Abdulaziz University and other academic medical centers in the nation investigated both
    trialsitenews.com


    Recently, a group of Saudi Arabian researchers from King Abdulaziz University and other academic medical centers in the nation investigated both Hydroxychloroquine (HCQ) and Favipiravir as possible COVID-19 treatments. Both drugs are used in many countries, including Saudi Arabia, during the pandemic for early-onset SARS-CoV-2 infection. Seeking to compare the effectiveness and safety of the two drugs, the investigational team, led by Aziza Al-Rafiah, conducted a retrospective cohort study evaluating the drugs’ impact on 508 patients admitted to King Faisal Medical Complex in Tarif, Saudi Arabia, from June 2020 to August 2020. The study authors indicate that both HCQ and Favipiravir appear to decrease mortality and need for oxygen, but a retrospective study such as this one has limitations. The safety signal for HCQ was stronger.


    Background

    During the first part of the pandemic in Saudi Arabia, health systems needed a rapid response, leveraging treatments that were thought to provide some benefit, including both HCQ and Favipiravir. Health care professionals used these treatments without collecting baseline data, from C-reactive protein (CRP) to D-dimer and lymphocyte count that could impact treatment allocation.


    The Study

    This retrospective study categorized patients into three cohorts including the following:


    Group # Patients %

    Favipiravir 244 55.8%

    HCQ 193 44.2%

    Neither 71 13.81%

    The Results

    The Saudi team reported recently that the Favipiravir group included a higher overall age of patient as well as greater comorbidity. While a majority of the patients were discharged by day 14 of the study (n = 303, 59.6%), 26 (36.6%) in the group that received neither medication, 154 (63.1%) in Favipiravir and 123 (63.7%) in the HCQ groups—the investigators reported a significant delta between groups (P<0.0001) as reported in Dovepress.


    But what about mortality rates? The team reported a mortality rate of 8.2% (n=20) in the Favipiravir group (mindful that this group had proportionally more elderly and reported comorbidity), and 7.3% (n=14) in the HCQ group of patients representing a significant delta between groups (P=0.048).


    Safety concerns were raised about HCQ last year. Meanwhile, Favipiravir, approved in Japan for influenza (stockpile), is also approved for COVID-19 in several nations from Russia to Thailand. 19.7% of the Favipiravir patients versus 7.8% of the HCQ patients experienced adverse effects with material differences between the groups (P>0.0001).


    The authors reported a majority of the side effects involved ALT and AST. A prolonged Q-T interval was documented solely in the HCQ group (2.6%).


    The Saudi authors performed a Cox regression model, declaring that only mechanical ventilation could predict mortality (HR: 16.598, 95% CI: 7.095-38.828, P<0.0001).


    Concerning discharge predictability, not one of the study drugs correlated with anticipating discharge. FPV vas HCQ)- (HR: 0.933, 95% CI: 0.729– 1.195, P = 0.5843), predictors of mortality were HCQ (vs FPV) (HR: 2.3, 95% CI: 0.994– 5.487, P = 0.0518). Kaplan–Meier survival curves showed improved survival time and discharged time among patients in the HCQ versus FPV group with an insignificant difference between them (P = 0.85, P = 0.06, respectively).


    Limitation

    Retrospective studies have several limitations well known but also can contribute to insight. The study was limited to patients hospitalized in one province of Saudi Arabia—the Taif province. Consequently, the researchers did not include a representative sampling of the entire population. While the investigators only used a dosing regimen for both HCQ and Favipiravir, multiple doses for safety evaluation are indicated.


    Conclusion

    The authors wrote that both Favipiravir and HCQ demonstrate similar efficacy in decreasing mortality and the need for oxygen. While Favipiravir “likely has a more favorable safety profile regarding cardiac toxicity,” the Saudi investigators conclude on the need for large, randomized controlled clinical trials to confirm their findings in COVID-19 patients.


    Lead Research/Investigator

    Aziza Al-Rafiah, Ph.D., Corresponding Author, Assistant Professor, Department of Laboratory Technology

  • After the yesterday strong increase (11-->14!!) in cases in Uttar Pradesh we had a steep decline (14-->8) today...


    They still try to find a CoV-19 death - among 205 mio. people - to satisfy our vaccine friends.


    How could Pfizer, Gillead, Merck,.. fail to bribe most of India's local state officials??? This will become a hard tribunal session during the next free masons meeting. I expect some low hanging bodies.


    קורונה - לוח בקרה

    Israel bad news again: > 10'000 cases yesterday despite boosters...


    This is what we expect from vaccine terror states!

  • It is somewhat unpredictable, as you describe. Some mass media reports say that people tend to react more to the second dose. There are reports that the Moderna vaccine tends to produce a stronger reaction and more discomfort. Nothing serious. They say it has a larger volume of active ingredients than Pfizer and that could be why it has more punch.


    Any vaccine will cause some side effects such as soreness. (He says, rubbing his arm.)

    It is well known that the second shot (to someone who has not have previous Covid) will usually yield a more adverse reaction than the first shot. But it could be that for those already having Covid, the first shot is worse that the second. This *may* translate to good news for those getting a 3rd (booster) shot : there may be a less adverse reaction than to the second shot.

  • Source'- brings it to my attention and I look around- 6 months later -


    External Content www.youtube.com
    Content embedded from external sources will not be displayed without your consent.
    Through the activation of external content, you agree that personal data may be transferred to third party platforms. We have provided more information on this in our privacy policy.

    no idea..

    Disinfecting or sterilization of public surfaces probably. Benches, outer clothing etc.


    External Content youtu.be
    Content embedded from external sources will not be displayed without your consent.
    Through the activation of external content, you agree that personal data may be transferred to third party platforms. We have provided more information on this in our privacy policy.


    quite useful but harsh on some skins.

  • there may be a less adverse reaction than to the second shot.

    This might depend on the vaccine. Israels today's data clearly shows that Pfizer induces CoV-19 . There is no other explanation for the steep increase in cases. Israel is vaccinating like mad. Also 16-19 year old did get boosters!! So far close to 3. mio boosters have been given.

    Still half of all severe cases (age > 70) are from double vaxx people. In younger its 1/3. Average vaccination rate is 80% now. So the vaccine protection (2..3x) from Pfizer remains low among age >70 ! (assuming 50% already had an infection/immunity)

  • This article says that conservatively, there have been 16,200 extra deaths since July 1, 2021 caused by undervaccination. More than that, I think.

    Or less. For many studies, they cheat. Specifically, one is not considered vaccinated until 14 days after vaccination! How convenient, since the 14 days after vaccination is exactly when people are most vulnerable to Covid.

  • Why must I be sure?? In the MA event it hit (>300) only double vaxxers. But please ask the DE government. I would like to know it too.


    = Lives lost by not early treating CoV-19!!

    You don‘t seem to know what 3G or 2G means in German….or didn‘t read the entire story….

    The event was open for 2G only. Geimpfte (vaccinated) und Genesene (went through a COVID-19 infection), both with official certificates (vaccination 2x, recovered from Cov-19) we’re allowed to enter. It doubt, that all 63 were only the ones who were vaccinated. This is your agenda only. Let’s wait for more details, if available at all.


    The question is, how strict this was handled…and there are ways to get such a certificate on the dark side of the moon….

  • It doubt, that all 63 were only the ones who were vaccinated. This is your agenda only.

    I have no agenda not like you. The chance for a "Genesener" (recovered) for an infection age < 50 is at least 40 x lower than for a vaccinated person.

    So be aware that 2G parties effectively are high risk zones due to the fact that vaccinated do not believe in an infection...

    No gen therapy (Pfizer, Moderna,Astra) protects you from a delta infection or from spreading it.

  • Stanford-led Study Demonstrates COVID-19 Hospitalized Patients Produce Self-Attacking Antibodies—Make a Case for Vaccination


    Stanford-led Study Demonstrates COVID-19 Hospitalized Patients Produce Self-Attacking Antibodies—Make a Case for Vaccination
    Stanford University investigators recently concluded in a study that 1 in 5 COVID-19 hospitalized patients develop new antibodies that attack their own
    trialsitenews.com


    Produce Self-Attacking Antibodies—Make a Case for Vaccination



    Stanford University investigators recently concluded in a study that 1 in 5 COVID-19 hospitalized patients develop new antibodies that attack their own tissue within a week of admission. Called autoantibodies, that is, antibodies directed at their own tissue or at substances their immune cells secrete into the blood, COVID-19 patients are far more likely to encounter this dynamic than those individuals without COVID-19. Autoantibodies potentially indicate the potential for autoimmune disease. The study results indicate that those that wind up hospitalized with COVID-19 “…may not be out of the woods,” suggests Stanford Medicine’s PJ Utz, lead researcher and professor of immunology and rheumatology.


    Published on September 14 in Nature Communications, the study team probed for autoantibodies in blood samples drawn during March and April of 2020 from 147 COVID-19 patients at the three university-affiliated hospitals in addition to a group of additional patients admitted to Kaiser Permanente. For the control group, the scientists included blood samples from additional donors.


    As reported in Stanford Medicine News, the research team both identified as well as measured levels of antibody targeting the virus in addition to autoantibodies and antibodies targeting cytokines, those proteins that immune cells secrete for communications and coordination.


    Findings

    Not surprisingly, the researchers discovered that 60% of all hospitalized COVID-19 patients carried anti-cytokine antibodies as compared to 1o 15% of the healthy controls. The study authors indicate that this observation is more than likely associated with “immune-system overdrive triggered by virulent, lingering infection.” Professor Utz suggested, “In the fog of war, the abundance of cytokines may trip off the erroneous production of antibodies targeting them.”


    The research team observed new antibodies in 20% of the patients after a week of admittance. These additional antibodies were not present upon hospital admittance. Professor Utz commented, “In many cases, these autoantibody levels were similar to what you’d see in a diagnosed autoimmune disease.”


    But what triggers the presence of these autoantibodies? According to Utz, one of the following factors could be present:


    Immune response-driven increase in antibodies that previously were present but in low levels

    Inflammatory shock associated with SARS-CoV-2 infection triggers jump in previously undetectable levels of innate autoantibodies

    Exposure to viral materials that resemble the patient’s own proteins

    Extended SARS-Cov-2 infection triggers greater immune response—leading to broken pieces of viral particles—human immune system may identify viral pieces as novel

    Making the Case for Vaccination

    Why could the argument be made that the results bolster the case for vaccination? The COVID-19 vaccines only contain one protein (spike protein), which is the genetic instructions to produce the spike protein. The authors state in Stanford Medicine News that “With vaccination, the immune system is never exposed to—and potentially confused by—the numerous other novel viral proteins generated during infection.”


    Study Funding

    National Institute of Health (NIH)

    The Henry Gustav Floren Trust

    The Parker Institute for Cancer Immunotherapy

    Sean N. Parker Center

    Frank Quattrone and Denise Foderaro Family Research Fund

    Chan Zuckerberg Biohub

    the Allen Institute for Immunology

    CEND COVID Catalyst Fund

    Chen Family Research Fund

    Carreras Foundation

    Foundation for Pathobiochemistry and Molecular Diagnostics

    Universities Giessen

    Marburg Lung Center

    German Center for Lung Research and the Deutsche Forschungsgemeinschaft

    Next Steps

    Stanford Medicine reports that Professor Utz seeks to further investigate SARS-CoV-2 infected blood samples of those asymptomatic or individuals that experienced mild COVID-19. The research question: Is the “massive hyperactivation of the immune system” causing the trouble, or could it be “the mere molecular resemblance of SARS-CoV-2 proteins?”


    Lead Research/Investigator

    PJ Utz, MD, Professor of Medicine, Immunology and Rheumatology.

    Sarah Chang, Department of Medicine, Division of Immunology and Rheumatology, Stanford University School of Medicine (Now at Genentech/Roche)

    Call to Action: Follow the link to the study in Nature Communications.


    New-onset IgG autoantibodies in hospitalized patients with COVID-19 - Nature Communications
    Infection with SARS-CoV2 and the development of Coronavirus disease 2019 (COVID-19) has been linked to induction of autoimmunity and autoantibody production.…
    www.nature.com

  • Another dot to follow in understanding Covid and how to treat. Treat early and treat all, non vaxed as well as breakthroughs


    University of Virginia School of Medicine-led Study Reveals Cholesterol Links to AD Plaque Formation


    University of Virginia School of Medicine-led Study Reveals Cholesterol Links to AD Plaque Formation
    Does brain-manufactured cholesterol play a role in the development of Alzheimer’s disease? According to recently published research led by scientists
    trialsitenews.com


    Does brain-manufactured cholesterol play a role in the development of Alzheimer’s disease? According to recently published research led by scientists at the University of Virginia School of Medicine and collaborators, the cholesterol produced by astrocytes is necessary for controlling the production of amyloid-beta, a sticky protein that develops in the brains of patients with Alzheimer’s. Accumulating into insoluble plaques that “are a hallmark of the disease,” waves of biotech development efforts target these plaques for removing or preventing them in the first place—all in the quest to treat or prevent Alzheimer’s. The new findings help point to how and why plaques form in the first place and could indicate why genes associated with cholesterol could be linked to a heightened risk for the disease.


    Writing for the University of Virginia School of Medicine News, John Barney recently reported on the notable research breakthroughs. Dr. Heather A. Ferris, UVA Health’s Division of Endocrinology and Metabolism, went on the record, “This study helps us to understand why genes linked to cholesterol are so important to the development of Alzheimer’s disease.” She continued, “Our data point to the importance of focusing on the production of cholesterol in astrocytes and the transport to neurons as a way to reduce amyloid-beta and prevent plaques from ever being formed.”


    A brief breakdown of this research topic led by the University of Virginia School of Medicine follows.


    Why is cholesterol also good?

    Good cholesterol is produced by the human body to help produce hormones that execute other important functions in the case of good cholesterol.


    What’s the key breakthrough of this research?

    Cholesterol may also help control the production of amyloid-beta and indicate more clarity on the role of astrocytes in Alzheimer’s disease. While scientists have realized that during Alzheimer’s, a patient’s common brain cells undergo significant changes, they were not sure if this was due to 1) impact from the disease itself or 2) contributing to the disease. The University of Virginia School of Medicine News’ Barney writes the new study results indicate the latter.


    What is the finding?

    When astrocytes make and distribute cholesterol to brain cells (neurons), this leads to more amyloid-beta generation, which in turn causes plaque communication. This, of course, very well may lead to Alzheimer’s.


    What’s the difference between normal state & AD?

    Neurons have low amounts of cholesterol in normal conditions, which minimizes amyloid-beta accumulation. However, with the onset of Alzheimer’s, neurons cannot modulate amyloid-beta leading to plaque formation.


    What did the researchers demonstrate in a preclinical lab study with mice?

    By setting up a preclinical study using mice, the researchers found that if they inhibit the astrocytes’ cholesterol production, they “robustly” lowered amyloid-beta production in the mice.


    Could this experiment be reproduced in humans?

    Possibly, but it is too soon to know.


    What are some parting thoughts?

    Given that amyloid-beta generation is tightly controlled, this suggests it would play a vital role in brain cells, writes University of Virginia’s Barney. Consequently, doctors could potentially need to consider how to inhibit or eliminate amyloid-beta.


    Who funded the research?

    · National Institutes of Health (NIH)


    · Owens Family Foundation


    Lead Research/Investigator

    Dr. Heather A. Ferris, MD, Ph.D., UVA Health’s Division of Endocrinology and Metabolism


    For other research authors, see the source.


    Call to Action: These findings have been published in the scientific journal PNAS.


    Regulation of beta-amyloid production in neurons by astrocyte-derived cholesterol
    The accumulation of amyloid β (Aβ) in the brain appears to be a necessary event in the pathogenesis of Alzheimer’s disease (AD). However, processes linked to…
    www.pnas.org


    SARS-CoV-2 infects brain astrocytes of COVID-19 patients and impairs neuronal viability

    SARS-CoV-2 infects brain astrocytes of COVID-19 patients and impairs neuronal viability
    COVID-19 patients may exhibit neuropsychiatric and neurological symptoms. We found that anxiety and cognitive impairment are manifested by 28-56% of…
    www.medrxiv.org

  • I have no agenda not like you. The chance for a "Genesener" (recovered) for an infection age < 50 is at least 40 x lower than for a vaccinated person.

    So be aware that 2G parties effectively are high risk zones due to the fact that vaccinated do not believe in an infection...

    No gen therapy (Pfizer, Moderna,Astra) protects you from a delta infection or from spreading it.

    Interesting data, can you share your source for this „at least 40x higher risk of infection for a vaccinated person vs a recovered person”? Thanks.

  • Stanford University investigators recently concluded in a study that 1 in 5 COVID-19 hospitalized patients develop new antibodies that attack their own tissue within a week of admission.

    That's why we call USA etc. vaccine terror states. A week after admission usually post day 15 of infection, when the deep pulmonary phase start to severely overshoot.


    99 of 100 would not reach the hospital if properly and early treated!


    the cholesterol produced by astrocytes is necessary for controlling the production of amyloid-beta, a sticky protein that develops in the brains of patients with Alzheimer’s. Accumulating into insoluble plaques that “are a hallmark of the disease,” waves of biotech development efforts target these plaques for removing or preventing them in the first place—all in the quest to treat or prevent Alzheimer’s.

    The first place where plaque occurs is the solar plexus or the guts nervous system. So here we see the same as with CoV-19. Detect early treat early. A stool transplantation can stop Alzheimer in an early state. No money for big pharma - despite it is known since 7 years now.


    Interesting data, can you share your source for this „at least 40x higher risk of infection for a vaccinated person vs a recovered person”? Thanks.

    May be once try to follow our thread. We linked all the papers - most from Israel - so they are Pfizer based and may be less precise for Moderna.


    What about a contribution from your side? Please find out how many got a re-infection in Münster!

  • That's why we call USA etc. vaccine terror states. A week after admission usually post day 15 of infection, when the deep pulmonary phase start to severely overshoot.

    That is a bit confusing. The study FM1 linked to was based on blood samples of hospitalized patients taken well before the first vaccinations began:


    Published on September 14 in Nature Communications, the study team probed for autoantibodies in blood samples drawn during March and April of 2020 from 147 COVID-19 patients at the three university-affiliated hospitals in addition to a group of additional patients admitted to Kaiser Permanente. For the control group, the scientists included blood samples from additional donors.

    So are you saying the vaccine provokes an autoimmune response from the virus: "post day 15 of infection, when deep pulmonary phase starts to severely overshoot"?

  • That is a bit confusing.

    Not at all. If you treat early days 1..5 latest nobody goes into a hospital. So all such studies are nice to have but only prove what fascists are willing to provoke to curb up vaccine sales.


    Also the follow up problem is caused by the fascist orders and treatment of CoV-19!


    The little-known virus that surged in children this year
    Doctors used to know RSV as a seasonal virus that emerged in the winter, but in the last few months there has been a surge in the Northern Hemisphere.
    www.bbc.com


    "Our ICU (intensive care unit) again became overwhelmed, this time not with Covid, but with another virus," recalls Rabia Agha, the director of the division of paediatric infectious diseases at Maimonides Children's Hospital. At the peak of the outbreak, in early April, the majority of children admitted into the ICU were being admitted for RSV.


    I simply no longer read all the stuff about damaged people. You can do the same after a wildfire: List all species killed...

    It's about Dr. Strangelow...

  • Or less. For many studies, they cheat. Specifically, one is not considered vaccinated until 14 days after vaccination! How convenient, since the 14 days after vaccination is exactly when people are most vulnerable to Covid.

    You have that backward. You said "or less." If they were to include people who got sick within 14 days, there would be more excess deaths, not fewer.


    I have not seen any reports that people are more vulnerable to COVID (or any other disease) some days after vaccination. On the contrary, doctors tell me that after 14 days, you are fully protected against whatever it is the vaccine is for, including COVID.

  • I will let you know, if your claim (at least 48x more infections among vaccinated) fits to the reality in Münster. So far 72 people in the age of 20…25, would mean ca. 2 students with natural immunity from Covid-19 infection were reinfected vs 70 double vaccinated…

  • To bring some claims into context me link another report that judges some of the „Israel data“…


    COVID infections may give more potent immunity than vaccines – but that doesn't mean you should try to catch it
    A new study from Israel on naturally acquired immunity has caused a stir – and some misinterpretation.
    theconversation.com


    In fact, the benefit of vaccination is not even addressed in the study since unvaccinated people without prior infection were not included for comparison. The low rate of COVID-related hospitalisations among vaccinated participants (eight out of 16,000) would probably be strikingly lower than among non-vaccinated people without prior infection, but this group was not included in the analyses.